Skip to main content

Table 1 The basic clinical characteristics of HCC patients with CC (n = 35) and TT (n = 16) genotype

From: Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D6*10 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker

Variables CC n (%) TT n (%) P
Age (year)    0.091
 ≤ 50 13 (37.14) 10 (62.50)  
 > 50 22 (62.86) 6 (37.50)  
Gender    0.370
 Man 31 (88.57) 13 (81.25)  
 Female 4 (11.43) 3 (18.75)  
PLT (× 109/L)    0.022
 < 180 23 (65.71) 5 (37.50)  
 ≥ 180 12 (34.29) 11 (62.50)  
ALT (U/L)    0.360
 ≤ 40 23 (65.71) 8 (50.00  
 > 40 12 (34.29) 8 (50.00)  
AST (U/L)    0.179
 ≤ 40 18 (51.43) 5 (31.25)  
 > 40 17 (48.57) 11 (68.75)  
Albumin/globulin    0.020
 ≤ 1.5 21 (60.00) 4 (33.33)  
 > 1.5 14 (40.00) 12 (66.67)  
ALB (g/L)    0.355
 ≤ 70 18 (51.43) 6 (37.50)  
 > 70 17 (48.57) 10 (62.50)  
TBIL (μmol/L)    0.009
 ≤ 17 20 (57.14) 15 (93.75)  
 > 17 15 (42.86) 1 (6.67)  
DBIL (μmol/L)    0.043
 ≤ 7 18 (51.43) 13 (81.25)  
 > 7 17 (48.57) 3 (18.75)  
ALP (U/L)    0.242
 ≤ 130 27 (77.14) 15 (93.75)  
 > 130 8 (22.86) 1 (6.67)  
AFP (ng/mL)    0.246
 ≤ 300 17 (48.57) 5 (31.25)  
 > 300 18 (51.43) 11 (68.75)  
PT (s)    0.043
 ≤ 14 26 (74.29) 16 (100.00)  
 > 14 9 (25.71) 0 (0)  
  1. P values were calculated from two‐side chi‐square test
  2. AFP: alpha-fetoprotein; ALB: albumin; ALT: alanine amino transferase; ALP: alkaline phosphatase; AST: Aspartate amino transferase; DBIL: direct bilirubin; PLT: platelet; PT: prothrombin time; TBIL: total bilirubin